Narayanaswami Vidya, Tong Junchao, Fiorino Ferdinando, Severino Beatrice, Sparaco Rosa, Magli Elisa, Giordano Flavia, Bloomfield Peter M, Prabhakaran Jaya, Mann J John, Vasdev Neil, Dahl Kenneth, Kumar J S Dileep
Azrieli Centre for Neuro-Radiochemistry, Research Imaging Centre & Preclinical Imaging, Centre for Addiction and Mental Health, Toronto, Ontario, M5T-1R8, Canada.
Department of Pharmacy, University of Naples, Via D. Montesano, 49, 8013, Naples, Italy.
EJNMMI Radiopharm Chem. 2020 May 19;5(1):13. doi: 10.1186/s41181-020-00096-8.
Serotonin 1A (5-HT) receptors are implicated in the pathogenesis of several psychiatric and neurodegenerative disorders motivating the development of suitable radiotracers for in vivo positron emission tomography (PET) neuroimaging. The gold standard PET imaging agent for this target is [carbonyl-C]WAY-100635, labeled via a technically challenging multi-step reaction that has limited its widespread use. While several antagonist and agonist-based PET radiotracers for 5-HT receptors have been developed, their clinical translation has been hindered by methodological challenges and/or and non-specific binding. As a result, there is continued interest in the development of new and more selective 5-HT PET tracers having a relatively easier and reliable radiosynthesis process for routine production and with favorable metabolism to facilitate tracer-kinetic modeling. The purpose of the current study was to develop and characterize a radioligand with suitable characteristics for imaging 5-HT receptors in the brain. The current study reports the in vitro characterization and radiosyntheses of three candidate 5-HT receptor antagonists, DF-100 (1), DF-300 (2) and DF-400 (3), to explore their suitability as potential PET radiotracers.
Syntheses of 1-3 and corresponding precursors for radiolabeling were achieved from isonicotinic, picolinic acid or picolino nitrile. In vitro binding studies demonstrated nanomolar affinity of the compounds for 5-HT receptors. Binding of 1-3 for other biogenic amines, neurotransmitter receptors, and transporters was negligible with the exception of moderate affinities for α-adrenergic receptors (4-6-fold less potent than that for 5-HT receptor). Radioligands [C]1-3 were efficiently prepared by C-O-methylation of the corresponding phenolic precursor in non-decay corrected radiochemical yields of 7-11% with > 99% chemical and radiochemical purities. Dynamic PET studies in rats demonstrated negligible brain uptake of [C]1 and [C]2. In contrast, significant brain uptake of [C]3 was observed with an early peak SUV of 4-5. However, [C]3 displayed significant off-target binding attributed to α-adrenergic receptors based on regional distribution (thalamus>hippocampus) and blocking studies.
Despite efficient radiolabeling, results from PET imaging experiments limit the application of [C]3 for in vivo quantification of 5-HT receptors. Nevertheless, derivatives of compound 3 may provide a scaffold for alternative PET radiotracers with improved selectivity for 5-HT receptors or α-adrenergic receptors.
血清素1A(5-HT)受体与多种精神疾病和神经退行性疾病的发病机制有关,这推动了适用于体内正电子发射断层扫描(PET)神经成像的放射性示踪剂的开发。用于该靶点的金标准PET成像剂是[羰基-C]WAY-100635,它通过一项技术上具有挑战性的多步反应进行标记,这限制了其广泛应用。虽然已经开发了几种基于拮抗剂和激动剂的5-HT受体PET放射性示踪剂,但它们的临床转化受到方法学挑战和/或非特异性结合的阻碍。因此,人们持续关注开发新的、更具选择性的5-HT PET示踪剂,这些示踪剂具有相对更简便可靠的放射性合成过程以便常规生产,并且具有良好的代谢特性以促进示踪剂动力学建模。本研究的目的是开发并表征一种具有合适特性的放射性配体,用于脑内5-HT受体成像。本研究报告了三种候选5-HT受体拮抗剂DF-100(1)、DF-300(2)和DF-400(3)的体外表征及放射性合成,以探索它们作为潜在PET放射性示踪剂的适用性。
1-3及其用于放射性标记的相应前体由异烟酸、吡啶甲酸或吡啶腈合成。体外结合研究表明这些化合物对5-HT受体具有纳摩尔亲和力。1-3与其他生物胺、神经递质受体和转运体的结合可忽略不计,但对α-肾上腺素能受体具有中等亲和力(效力比5-HT受体低4-6倍)。通过相应酚类前体的C-O甲基化高效制备了放射性配体[C]1-3,未校正衰变的放射化学产率为7-11%,化学和放射化学纯度均>99%。大鼠的动态PET研究表明,[C]1和[C]2在脑中的摄取可忽略不计。相比之下,观察到[C]3在脑中的摄取显著,早期SUV峰值为4-5。然而,基于区域分布(丘脑>海马体)和阻断研究,[C]3显示出归因于α-肾上腺素能受体的显著非靶向结合。
尽管放射性标记效率高,但PET成像实验结果限制了[C]3在体内定量5-HT受体方面的应用。尽管如此,化合物3的衍生物可能为替代PET放射性示踪剂提供一个支架,这些示踪剂对5-HT受体或α-肾上腺素能受体具有更高的选择性。